ATM突变与NSCLC中的明显的共同突变模式和治疗脆弱性有关
Natalie I Vokes1,2, Ana Galan Cobo3, Margarita Fernandez-Chas4
1Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
概括
在非小细胞肺癌 (NSCLC) 中发生的阿塔克西亚-泰朗格iectasia 突变 (ATM) 基因突变与 KRAS 突变相关,并且通过化疗加上免疫检查点抑制剂改善了结局.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 突变的阿塔克西亚-泰朗吉克塔西亚 (ATM) 是一种关键的DNA损伤修复基因,在非小细胞肺癌 (NSCLC) 中经常发生变化.
- 在NSCLC中ATM突变的分子格局和临床影响仍然不完全理解.
研究的目的:
- 阐明NSCLC中ATM突变的分子相关性.
- 研究ATM突变的临床影响,特别是对免疫检查点抑制剂 (ICI) 的反应.
主要方法:
- 分析了超过26,000名NSCLC患者的临床病理学和基因组数据.
- 评估ATM突变的同时发生,蛋白质表达和突变过程.
- 在接受ICI治疗的患者中,评估ATM相关的结果,有或没有化疗.
- 关于ATM损失,STING信号和化疗敏感性的临床前研究.
主要成果:
- 在11.2%的NSCLC样本中发生了ATM突变,与KRAS突变显著相关,与EGFR突变相互排斥.
- 机器人机器人突变显示出与KRAS,TP53和KEAP1.1不同的共同突变模式.
- 功能障碍的ATM突变与接受ICI加化疗的患者的整体存活率 (OS) 的改善有关,但不仅仅是ICI.
- 实验室研究显示,ATM缺乏细胞中的STING信号传递和化疗敏感性增强.
结论:
- ATM突变识别出一种独特的NSCLC亚型,其特征是KRAS突变,高瘤突变负担 (TMB) 和改变的共同突变概况.
- 在ATM突变的NSCLC中,可能会对ICI和DNA破坏性化疗的联合疗法表现出增加的敏感性.
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
Cancers Originate from Somatic Mutations in a Single Cell
12.0K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
12.0K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
DNA Damage can Stall the Cell Cycle
9.2K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
Mismatch Repair
4.9K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K


